Issues and controversies in the treatment of HER2 positive metastatic breast cancer

Surabhi Amar, Alvaro Moreno Aspitia, Edith A. Perez

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Targeted therapies against the human epidermal growth factor receptor HER2, have led to revolutionary strides in breast cancer research and treatment. Clinical therapeutic decisions in the treatment of patients with HER2 positive metastatic breast cancer are based on appropriate patient selection, the clinical situation, and data related to the available therapeutic agents trastuzumab and lapatinib. Trastuzumab was the first agent tested and approved in 1996 as single agent for patients with chemotherapy-refractory disease, and in combination with paclitaxel as first-line treatment. This intravenous humanized monoclonal antibody is directed against the extracellular domain of the HER2 protein. Lapatinib, an oral small molecule tyrosine kinase inhibitor has more recently become available (in 2007), approved for used in combination with capecitabine for patients with HER2 positive metastatic disease that has progressed on trastuzumab. Important questions and controversies still remain and are reviewed, including patient selection for anti-HER2 treatment of metastatic disease based on HER2 testing, dose scheduling of trastuzumab, duration of therapy, tolerability, role of lapatinib and clinical significance of trastuzumab resistance and efficacy. Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalBreast Cancer Research and Treatment
Volume109
Issue number1
DOIs
StatePublished - May 2008

Fingerprint

Breast Neoplasms
Therapeutics
Patient Selection
Intravenous Immunoglobulins
Proxy
Paclitaxel
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Trastuzumab
Drug Therapy
Research
lapatinib

Keywords

  • HER2 positive
  • Lapatinib
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Issues and controversies in the treatment of HER2 positive metastatic breast cancer. / Amar, Surabhi; Moreno Aspitia, Alvaro; Perez, Edith A.

In: Breast Cancer Research and Treatment, Vol. 109, No. 1, 05.2008, p. 1-7.

Research output: Contribution to journalArticle

@article{996b1825196e4aba89e12a03268c0b61,
title = "Issues and controversies in the treatment of HER2 positive metastatic breast cancer",
abstract = "Targeted therapies against the human epidermal growth factor receptor HER2, have led to revolutionary strides in breast cancer research and treatment. Clinical therapeutic decisions in the treatment of patients with HER2 positive metastatic breast cancer are based on appropriate patient selection, the clinical situation, and data related to the available therapeutic agents trastuzumab and lapatinib. Trastuzumab was the first agent tested and approved in 1996 as single agent for patients with chemotherapy-refractory disease, and in combination with paclitaxel as first-line treatment. This intravenous humanized monoclonal antibody is directed against the extracellular domain of the HER2 protein. Lapatinib, an oral small molecule tyrosine kinase inhibitor has more recently become available (in 2007), approved for used in combination with capecitabine for patients with HER2 positive metastatic disease that has progressed on trastuzumab. Important questions and controversies still remain and are reviewed, including patient selection for anti-HER2 treatment of metastatic disease based on HER2 testing, dose scheduling of trastuzumab, duration of therapy, tolerability, role of lapatinib and clinical significance of trastuzumab resistance and efficacy. Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed.",
keywords = "HER2 positive, Lapatinib, Metastatic breast cancer, Trastuzumab",
author = "Surabhi Amar and {Moreno Aspitia}, Alvaro and Perez, {Edith A.}",
year = "2008",
month = "5",
doi = "10.1007/s10549-007-9636-2",
language = "English (US)",
volume = "109",
pages = "1--7",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Issues and controversies in the treatment of HER2 positive metastatic breast cancer

AU - Amar, Surabhi

AU - Moreno Aspitia, Alvaro

AU - Perez, Edith A.

PY - 2008/5

Y1 - 2008/5

N2 - Targeted therapies against the human epidermal growth factor receptor HER2, have led to revolutionary strides in breast cancer research and treatment. Clinical therapeutic decisions in the treatment of patients with HER2 positive metastatic breast cancer are based on appropriate patient selection, the clinical situation, and data related to the available therapeutic agents trastuzumab and lapatinib. Trastuzumab was the first agent tested and approved in 1996 as single agent for patients with chemotherapy-refractory disease, and in combination with paclitaxel as first-line treatment. This intravenous humanized monoclonal antibody is directed against the extracellular domain of the HER2 protein. Lapatinib, an oral small molecule tyrosine kinase inhibitor has more recently become available (in 2007), approved for used in combination with capecitabine for patients with HER2 positive metastatic disease that has progressed on trastuzumab. Important questions and controversies still remain and are reviewed, including patient selection for anti-HER2 treatment of metastatic disease based on HER2 testing, dose scheduling of trastuzumab, duration of therapy, tolerability, role of lapatinib and clinical significance of trastuzumab resistance and efficacy. Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed.

AB - Targeted therapies against the human epidermal growth factor receptor HER2, have led to revolutionary strides in breast cancer research and treatment. Clinical therapeutic decisions in the treatment of patients with HER2 positive metastatic breast cancer are based on appropriate patient selection, the clinical situation, and data related to the available therapeutic agents trastuzumab and lapatinib. Trastuzumab was the first agent tested and approved in 1996 as single agent for patients with chemotherapy-refractory disease, and in combination with paclitaxel as first-line treatment. This intravenous humanized monoclonal antibody is directed against the extracellular domain of the HER2 protein. Lapatinib, an oral small molecule tyrosine kinase inhibitor has more recently become available (in 2007), approved for used in combination with capecitabine for patients with HER2 positive metastatic disease that has progressed on trastuzumab. Important questions and controversies still remain and are reviewed, including patient selection for anti-HER2 treatment of metastatic disease based on HER2 testing, dose scheduling of trastuzumab, duration of therapy, tolerability, role of lapatinib and clinical significance of trastuzumab resistance and efficacy. Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed.

KW - HER2 positive

KW - Lapatinib

KW - Metastatic breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=42149106859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149106859&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9636-2

DO - 10.1007/s10549-007-9636-2

M3 - Article

C2 - 17653858

AN - SCOPUS:42149106859

VL - 109

SP - 1

EP - 7

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -